Thermo Fisher Scientific at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Thermo Fisher Scientific brings 4 presentations to ESGCT 2026 in Hamburg. Its contributions centre on scaling viral vector production, from high-throughput AAV screens up to large bioreactors and lentiviral supply for use inside or outside the body. It also looks at what AAV manufacturing costs and how plasmid choices affect yield and quality.
| Organization | ESGCT 2026 Attendance |
|---|---|
Thermo Fisher Scientific Waltham, Massachusetts | |
Supplies laboratory instruments, reagents and consumables, and offers viral vector and cell therapy manufacturing through its contract services business. | Poster Wed Oct 28 1:30pm–3:30pm Scalable AAV upstream development from high-throughput systems to 2000 L Poster Wed Oct 28 1:30pm–3:30pm Scalable lentiviral vector manufacturing for ex-vivo and in-vivo gene therapy applications Poster Thu Oct 29 2:00pm–4:00pm Economics of rAAV manufacturing and cost reduction strategies Poster Thu Oct 29 2:00pm–4:00pm Impact of DNA Technology and Plasmid Ratios on AAV Vector Yield and Product Quality |
Instantly find 20 buyers from Thermo Fisher Scientific
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction